PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.662 – $0.737
Volume7,511
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for PRFX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for PRFX.
Recent news
Company coverage with links to the original publishers.
PRF Technologies announced FDA clearance of its Investigational New Drug (IND) application for OcuRing™-K, a bio-erodible intraocular ring designed to deliver ketorolac for post-cataract surgery pain and inflammation. The company plans to initiate a Phase II clinical trial in the United States with patient enrollment expected in the second half of 2026. OcuRing™-K aims to eliminate the need for complex post-surgical eye-drop regimens by providing sustained, localized drug release through a single intraoperative application.
PRF Technologies (NASDAQ: PRFX) shares tumbled on Tuesday as the broader market traded lower and investors digested the company's year-end business update. The stock, down 76.25% over the past 12 months, continues to face headwinds despite the company's strategic repositioning into a diversified platform spanning specialty pharmaceuticals and AI-driven solar analytics. Key 2025 initiatives included a majority investment in LayerBio for ocular drug delivery and the acquisition of DeepSolar for solar analytics, but traders remain skeptical of converting these initiatives into sustainable revenue.
PainReform's DeepSolar business unit launched Smart TDD, an advanced solar Technical Due Diligence service designed to provide faster and more comprehensive assessments of solar asset performance. The service targets the $60+ billion annual solar asset M&A market by offering complete data coverage, AI-driven diagnostics, and rapid turnaround to support investors, operators, insurers, and lenders across the solar asset lifecycle.
BladeRanger (TASE: BLRN), a drone-based inspection and AI analytics provider for green energy infrastructure, will showcase its Solar Drone and DeepSolar platforms at Abu Dhabi Sustainability Week. The company is expanding its regional presence in the UAE, where $600 billion is being invested in hyperscale data centers and renewable energy systems. BladeRanger has held strategic meetings with major regional energy organizations including ADNOC, TAQA, and Masdar.
PainReform Ltd. has acquired a majority equity stake in LayerBio, a biotechnology company developing a breakthrough non-opiate, non-steroidal drug delivery system for postoperative pain management in cataract surgery, targeting the $9B global market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.